세계의 분자종양 진단 시장 : 제품, 기술, 암 유형, 최종 사용자별 예측(2025-2030년)

The Molecular Oncology Diagnostics Market was valued at USD 8.84 billion in 2023, expected to reach USD 9.88 billion in 2024, and is projected to grow at a CAGR of 11.83%, to USD 19.36 billion by 2030.

Molecular Oncology Diagnostics is a rapidly evolving field focused on the detection and characterization of cancer through molecular-based techniques, such as genomics, proteomics, and metabolomics. The necessity for these diagnostics stems from the need for precise and personalized cancer treatment strategies, improving early detection, prognosis, and therapeutic outcomes. Applications range from identifying specific genetic mutations associated with cancer to monitoring the effectiveness of ongoing treatments. The end-use scope spans across hospitals, diagnostic laboratories, and research institutes, relying on advanced technologies like next-generation sequencing (NGS) and polymerase chain reaction (PCR).

Market insights reveal that the growth of Molecular Oncology Diagnostics is driven by increased cancer prevalence, advancements in molecular diagnostics technology, and the rising demand for precision medicine. Strategic partnerships and mergers among key players are also fostering market expansion. Opportunities lie in developing cost-effective and more accessible diagnostic tools, which could tap into emerging markets with insufficient healthcare infrastructure. The integration of AI and machine learning in diagnostic processes holds promising potential for early and more accurate detection of malignancies. However, challenges persist, including the high costs of advanced diagnostic techniques, the complexity of data interpretation, and stringent regulatory requirements that can impede rapid market entry.

To capitalize on opportunities, companies should focus on R&D in non-invasive liquid biopsies and expand the scope of companion diagnostics that can predict patient responses to specific cancer treatments. Best areas of innovation include the development of point-of-care diagnostic solutions and the enhancement of bioinformatics to analyze complex cancerous genomic data efficiently. The market is competitive yet dynamic, emphasizing both the adoption of novel technologies and strategic collaborations to strengthen market position. Despite the challenges, companies that invest in overcoming these limitations and prioritize innovation are likely to gain a competitive advantage, leading to substantial business growth in the Molecular Oncology Diagnostics market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Molecular Oncology Diagnostics Market

The Molecular Oncology Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of cancer cases and aging population
  • Rising need for automated and advanced diagnostic techniques
  • Favorable health reimbursement and the trend toward personalized medicine
• Market Restraints
  • High cost associated with molecular oncology diagnostics test
• Market Opportunities
  • Ongoing investments in R&D activities in oncology diagnostics
  • Technological advancements in molecular biology and biotechnology
• Market Challenges
  • Stringent regulatory hurdles coupled with a lack of consistent standards in molecular diagnostic techniques

Porter's Five Forces: A Strategic Tool for Navigating the Molecular Oncology Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Molecular Oncology Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Molecular Oncology Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Molecular Oncology Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Molecular Oncology Diagnostics Market

A detailed market share analysis in the Molecular Oncology Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Molecular Oncology Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Molecular Oncology Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Molecular Oncology Diagnostics Market

A strategic analysis of the Molecular Oncology Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Molecular Oncology Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocartis NV, Biocept, Inc., BIOMERIEUX SA, Danaher Corporation, DiaSorin Molecular LLC, Enzo Biochem, Inc., F. Hoffmann-La Roche Ltd., GenMark Saglik, Hologic, Inc., Illumina, Inc., Leica Biosystems Nussloch GmbH, Myriad Genetics, Inc., NeoGenomics Laboratories, OncoCyte Corporation, PathAI, Inc., Personal Genome Diagnostics Inc., QIAGEN N.V., Siemens AG, Sysmex Asia Pacific Pte Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Molecular Oncology Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Instruments and Reagents.
• Based on Technology, market is studied across Chips & Microarrays, In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology (INAAT), Mass Spectrometry, Multiplex, PCR, Sequencing, and Transcription Mediated Amplification.
• Based on Cancer Type, market is studied across Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, and Prostate Cancer.
• Based on End User, market is studied across Diagnostic Centers and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of cancer cases and aging population
    • 5.1.1.2. Rising need for automated and advanced diagnostic techniques
    • 5.1.1.3. Favorable health reimbursement and the trend toward personalized medicine
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with molecular oncology diagnostics test
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing investments in R&D activities in oncology diagnostics
    • 5.1.3.2. Technological advancements in molecular biology and biotechnology
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory hurdles coupled with a lack of consistent standards in molecular diagnostic techniques
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Molecular Oncology Diagnostics Market, by Product

• 6.1. Introduction
• 6.2. Instruments
• 6.3. Reagents

7. Molecular Oncology Diagnostics Market, by Technology

• 7.1. Introduction
• 7.2. Chips & Microarrays
• 7.3. In Situ Hybridization
• 7.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
• 7.5. Mass Spectrometry
• 7.6. Multiplex
• 7.7. PCR
• 7.8. Sequencing
• 7.9. Transcription Mediated Amplification

8. Molecular Oncology Diagnostics Market, by Cancer Type

• 8.1. Introduction
• 8.2. Blood Cancer
• 8.3. Breast Cancer
• 8.4. Cervical Cancer
• 8.5. Colorectal Cancer
• 8.6. Kidney Cancer
• 8.7. Liver Cancer
• 8.8. Lung Cancer
• 8.9. Prostate Cancer

9. Molecular Oncology Diagnostics Market, by End User

• 9.1. Introduction
• 9.2. Diagnostic Centers
• 9.3. Hospitals

10. Americas Molecular Oncology Diagnostics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Molecular Oncology Diagnostics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Molecular Oncology Diagnostics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Agilent Technologies, Inc.
• 3. Bayer AG
• 4. Becton, Dickinson and Company
• 5. Bio-Rad Laboratories, Inc.
• 6. Biocartis NV
• 7. Biocept, Inc.
• 8. BIOMERIEUX SA
• 9. Danaher Corporation
• 10. DiaSorin Molecular LLC
• 11. Enzo Biochem, Inc.
• 12. F. Hoffmann-La Roche Ltd.
• 13. GenMark Saglik
• 14. Hologic, Inc.
• 15. Illumina, Inc.
• 16. Leica Biosystems Nussloch GmbH
• 17. Myriad Genetics, Inc.
• 18. NeoGenomics Laboratories
• 19. OncoCyte Corporation
• 20. PathAI, Inc.
• 21. Personal Genome Diagnostics Inc.
• 22. QIAGEN N.V.
• 23. Siemens AG
• 24. Sysmex Asia Pacific Pte Ltd.
• 25. Thermo Fisher Scientific Inc.